Pfizer has acquired commercial-stage biopharmaceutical firm Biohaven Pharmaceutical for $148.50 for each share or a total consideration of nearly $11.6bn in cash.

In May, Pfizer entered a definitive agreement to acquire all outstanding shares of Biohaven which were not previously held by the former. 

With the takeover, Biohaven became a wholly-owned Pfizer subsidiary.

Treatments to enhance the lives of debilitating neurological and neuropsychiatric disease patients are part of Biohaven’s portfolio. 

Through the latest acquisition, Pfizer will add a breakthrough calcitonin gene-related peptide (CGRP) portfolio, including NURTEC ODT (rimegepant).

A CGRP receptor antagonist, NURTEC ODT is approved by the US Food and Drug Administration (FDA) for use in adults for acute treatment of migraine irrespective of aura status as well as for preventive episodic migraine treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is also approved in the EU under the trade name Vydura for use in similar indications.

Zavegepant, another CGRP receptor antagonist, is expected to receive approval as an intranasal spray from the FDA for the acute treatment of migraine in the first quarter of next year.

Additionally, Pfizer will gain access to a portfolio of pre-clinical CGRP assets of Biohaven with the takeover.

Pfizer executive vice-president and chief business innovation officer Aamir Malik said: “We are proud to build on Pfizer’s legacy of delivering breakthrough medicines for patients living with complex pain disorders. 

“The success of NURTEC ODT coupled with Biohaven’s CGRP pipeline will strengthen Pfizer’s innovative Internal Medicine pipeline through 2030 and beyond. 

“Combined with Pfizer’s global reach, this acquisition increases our potential to bring new treatment options to patients with migraine – a disease which affects over one billion people worldwide.”